Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-HLA-DR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human HLA-DR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-HLA-DR antibody linked to CD28 and CD3ζ signaling domains.
|
CAR Construction : huLym-1-B-41BB-CD3ζ
Fig.1 CAR-T cell viability. Percent viability measurement of subcultured 89Zr-oxine labeled and unlabeled huLym-1-A-BB3z-CAR T-cells on day 0, 1, 2, and 4 time points, respectively. Sta Maria, N. S., Khawli, L. A., Pachipulusu, V., Lin, S. W., Zheng, L., Cohrs, D., ... & Jacobs, R. E. (2021). Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model. Scientific Reports, 11(1), 1-13. |
|
CAR Construction : huLym-1-B-41BB-CD3ζ
Fig.2 Cytokine release by CAR-transduced T cells. IL-2 and IFN-γ cytokines released by 89Zr-oxine labeled and unlabeled mock and huLym-1-A-BB3z-CAR T-cells. Sta Maria, N. S., Khawli, L. A., Pachipulusu, V., Lin, S. W., Zheng, L., Cohrs, D., ... & Jacobs, R. E. (2021). Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model. Scientific Reports, 11(1), 1-13. |
|
CAR Construction : huLym-1-B-41BB-CD3ζ
Fig.3 Cytotoxicity assay in vitro. Cytotoxicity of 89Zr-oxine labeled and unlabeled mock and huLym-1-A-BB3z-CAR T-cells against Lym-1-positive Raji cells. Sta Maria, N. S., Khawli, L. A., Pachipulusu, V., Lin, S. W., Zheng, L., Cohrs, D., ... & Jacobs, R. E. (2021). Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model. Scientific Reports, 11(1), 1-13. |
|
CAR Construction : huLym-1-B-41BB-CD3ζ
Fig.4 huLym-1-B CAR T cells mediate superior antitumor efficacy. Schematic representation of the in vivo study. NSG mice inoculated with 10^6 Raji-eGFP/Luc on day 0, followed by treatment of 106Mock, huLym-1-B-DAP, or huLym-1-B-BB3z CAR T cells on day 8. Zheng, L., Ren, L., Kouhi, A., Khawli, L. A., Hu, P., Kaslow, H. R., & Epstein, A. L. (2020). A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma ModelshuLym-1-B CAR with DAP10 and DAP12 Signaling Domains. Clinical Cancer Research, 26(14), 3694-3706. |
|
CAR Construction : huLym-1-B-41BB-CD3ζ
Fig.5 Kaplan–Meier curve of survival test. The survival test of huLym-1-B CAR T cells against Raji tumors in NSG mice. Zheng, L., Ren, L., Kouhi, A., Khawli, L. A., Hu, P., Kaslow, H. R., & Epstein, A. L. (2020). A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma ModelshuLym-1-B CAR with DAP10 and DAP12 Signaling Domains. Clinical Cancer Research, 26(14), 3694-3706. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-HLA-DR (huLym-1-B) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-0120ZP219). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
